Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW.

Arch Gen Psychiatry. 2002 Nov;59(11):1021-6.

PMID:
12418935
2.

Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.

Lambert BL, Chang KY, Tafesse E, Carson W.

J Clin Psychopharmacol. 2005 Feb;25(1):12-8.

PMID:
15643095
3.

Hyperlipidemia following treatment with antipsychotic medications.

Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ.

Am J Psychiatry. 2006 Oct;163(10):1821-5.

PMID:
17012695
4.

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.

Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA.

J Clin Psychiatry. 2002 Oct;63(10):920-30.

PMID:
12416602
6.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW.

BMJ. 2002 Aug 3;325(7358):243.

9.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
10.

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL.

J Clin Psychiatry. 2000 Nov;61(11):833-40.

PMID:
11105736
11.

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.

Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.

Schizophr Res. 2003 Jun 1;61(2-3):303-14.

PMID:
12729882
12.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400
13.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A.

J Clin Psychiatry. 2003 Sep;64(9):998-1004.

PMID:
14628974
14.

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.

Fuller MA, Shermock KM, Secic M, Grogg AL.

Pharmacotherapy. 2003 Aug;23(8):1037-43.

PMID:
12921249
15.

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A.

J Sex Marital Ther. 2003 Mar-Apr;29(2):125-47.

PMID:
12623765
16.

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.

Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA.

J Clin Psychiatry. 2002 May;63(5):408-13.

PMID:
12019665
17.

[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].

Rubio G, Gómez-de-la-Cámara A, Ledesma F, Burón JA, Rodríguez-Morales A, Martínez-Junquera G; Grupo Español para el Estudio de la Diabetes en Pacientes Esquizofrénicos.

Med Clin (Barc). 2006 Apr 1;126(12):441-4. Spanish.

PMID:
16620729
18.

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.

Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D.

Clin Ther. 2003 Apr;25(4):1150-71.

PMID:
12809963
19.

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.

Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW.

Neuropsychopharmacology. 2003 Jan;28(1):182-92.

20.

Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.

Dinakar HS, Sobel RN, Bopp JH, Daniels A, Mauro S.

Psychiatr Serv. 2002 Jun;53(6):755-7.

PMID:
12045315

Supplemental Content

Support Center